



Original Article

Impact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial

Reza Rastgoo¹ , Mahnaz Yousefi Ramandi², Fereshteh Ebrahimi¹, Reza Madadi^{2*} , Hamid Khederlou², Ali Ramazani^{1*}

¹Department Pharmaceutical Biotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran

²Department of Cardiology, Zanjan University of Medical Sciences, Zanjan, Iran

Article info

Article History:

Received: August 7, 2025

Revised: September 22, 2025

Accepted: February 18, 2026

Published: June 30, 2026

*Corresponding Authors:

Ali Ramazani,

Email: ramazania@zums.ac.ir,

Reza Madai,

Email: r_madady2000@zums.ac.ir

Abstract

Introduction: Given the proven cardiovascular benefits of Empagliflozin (EM), we aimed to investigate the effect of Empagliflozin on Cardiotrophin-1 (CTF-1) and growth differentiation factor-15 (GDF-15) expressions in circulating monocytes in type 2 diabetic patients after MI.

Methods: This randomized, double-blind, placebo-controlled study included 33 patients referred to Ayatollah Mousavi Hospital in Zanjan between 5 of September to 25 of December, 2024. Eligible patients with type 2 diabetes and MI who underwent primary percutaneous coronary intervention (PCI) were randomly assigned (17:16) to receive either 10 mg of EMPA daily or placebo for 12 weeks. Target genes expression levels were quantified by real time PCR, and data were analyzed by SPSS version 26.

Results: Thirty-three patients were included in this study (mean age: 61.27 ± 9.07 , 66% male), mean diabetes duration was longer in intervention group (7.82 ± 5.13) compared to placebo group (3.75 ± 2.74), hypertension was the most common comorbidity (57%). CTF-1 expression in the intervention group was 0.3 ± 0.28 and in placebo group was 5.66 ± 6.52 . GDF-15 expression in the intervention group was 0.198 ± 0.22 and in placebo group was 1.66 ± 1.04 . EMPA significantly reduced expression of CTF-1 (13-fold) ($P=0.003$) and GDF-15 (7-fold) ($P < 0.0001$). The CTF-1 and GDF-15 expression reduction were not associated with any other clinical variables. Significant reduction observed in LDL ($P=0.045$) and triglycerides ($P=0.013$) after intervention.

Conclusion: EMPA significantly reduced the expression of CTF-1 and GDF-15 in type 2 diabetic, post MI patients, which are associated with atherosclerosis, and suggest that potential anti-atherosclerotic effect of EMPA mediated through modulation of GDF-15 and CTF-1 gene expression.

Keywords: Empagliflozin, Cardiotrophin-1, Growth differentiation factor-15, Diabetes mellitus, Blood sugar, Myocardial infarction

Introduction

Myocardial infarction (MI) is one of the most severe acute kind of cardiovascular disease.¹ MI most commonly results from the rupture of vulnerable atherosclerotic plaques and subsequent coronary artery thrombosis.^{2,3} Subsequent to a myocardial infarction (MI), atherosclerotic plaques may indeed experience accelerated growth and increased complexity, thereby heightening the risk of another MI.⁴ Moreover, MI is influenced by both traditional and novel risk. Traditional risk factors include type 2 diabetes mellitus (T₂DM), obesity, dyslipidemia, family history of heart disease and novel risk factors such as chronic inflammation, autoimmune diseases,⁵ thrombopoietin⁶ and cardiac biomarkers like cardiostrophin-1 (CTF-1).⁷

T₂DM is a chronic metabolic disorder⁸ that accounts for about 90% of diabetic population in world.⁹ Macrovascular complications of T₂DM include coronary arteries, peripheral arteries and cerebrovasculature, with an annual incidence of 1.4 - 4.7% of patients.^{10,11} There are different oral medicines for T₂DM treatment management such as metformin, sulfonylureas, sodium-glucose co-transporter 2 inhibitors (SGLT2Is), dipeptidyl peptidase 4 inhibitors, and the choice of treatment depends on patient's clinical conditions. Empagliflozin (EMPA) is a member of SGLT2I that used in T₂DM treatment. EMPA increases urinary glucose excretion, causes glucose reduction, lowers body weight and blood pressure.¹² EMPA is utilized in the management of T₂DM, as well as for individuals who have



concurrent cardiovascular conditions, particularly heart failure.¹²⁻¹⁶ Furthermore, through an unidentified process, EMPA may diminish oxidative stress and the generation of free radicals. This indicates that the protective benefits of EMPA could go beyond its established mechanisms, such as regulating blood sugar, and may engage in a more essential interaction with the body's antioxidant defenses.¹⁴

Biomarkers in body are used for diagnosis, prognosis, prediction and monitoring therapeutic responses.¹⁷ Among cardiovascular and diabetic biomarkers, Galectin-3, cardiotrophin-1 (CTF-1) and growth differentiation factor-15 (GDF-15) are of particular interest.¹⁸ Evidence indicates that EMPA can modulates CTF-1 and GDF-15 expression levels.¹⁹⁻²¹ CTF-1 is one of cardiovascular and diabetic biomarkers, a member of interleukin-6 cytokine family²² that can exert its effects by binding to gp130 and Leukemia Inhibitory Factor Receptor (LIFR).²³ CTF-1 is produced by myocardial cells of the heart²², vascular endothelial cells, macrophages, and adipose tissue.^{24,25} Its expression varies among these tissues; instead, it demonstrates functions that are specific to each tissue. In the heart, increased CTF-1 expression is associated with cardiac hypertrophy,^{23,26} in adipose tissue, it promotes lipolysis and reduce insulin resistance²⁷ and in vascular endothelial cells, atherosclerotic plaques, and macrophages it initiates inflammatory processes. CTF-1 stimulate expression of interleukin-6, interleukin-1 β and *TNF- α* in monocytes,²⁶⁻³⁰ enhanced monocytes adhesion and migration into atherosclerotic plaques³⁰ and has been shown in ApoE^{-/-} mice to be highly expressed in macrophages, that accelerates plaques progression.²⁴ GDF-15 biomarker also known as macrophage inhibitory cytokine-1 (MIC-1), belongs to the transforming growth factor beta (TGF- β) superfamily.³¹ GDF-15 is generally found at low concentrations in the majority of tissues under standard physiological circumstances.²¹ Nevertheless, its expression is markedly increased in response to stress and tissue injury. Although the placenta serves as the main source of elevated GDF-15 levels during pregnancy, it is also produced in higher amounts in several pathological states, particularly those involving endothelial cells, vascular smooth muscle cells, and adipose tissue.³² Higher concentration of GDF-15 associated with arterial fibrillation risk³³ and mortality in chronic heart failure patients.³¹ GDF-15 has been shown to enlarge atherosclerotic plaques and increase plaque vulnerability.³⁴

In this study we aimed to investigate potential anti-atherosclerosis effect of Empagliflozin by evaluating its impact on CTF-1 and GDF-15 expression in peripheral blood in patients with T₂DM after MI undergoing primary PCI.

Material and Methods

Study design

The trial was a randomized, double-blind, placebo-controlled trial, in which T₂DM patients post-ST-segment

elevation MI (STEMI) underwent primary percutaneous coronary intervention (PCI) were randomly assigned to EMPA 10 mg daily or matching placebo (1:1) for 12 weeks between September 5 to December 25, 2024. Our study was approved by the Ethic Committee of Zanjan University of Medical Sciences (Ethical code: IR.ZUMS.REC.1403.154), and the protocol was prospectively registered on the Iranian Registry of Clinical Trials (www.IRCT.ir, IRCT code: IRCT20241106063619N1).

The inclusion criteria of patients were T₂DM patients with HbA1c between 6.5-8% treated with metformin, sulfonylurea, and other anti-diabetic agents or combination of all of these medicines, and patients with typical chest pain during the 12 hours prior to assessment that lasting longer than 30 minutes, along with an ST-segment elevation above 0.1 mV in 2 anatomically contiguous leads or ≥ 2 mm in leads V2 and V3 or new left bundle branch block in ECG. The exclusion criteria was cardiogenic shock, hypoglycemia, diabetic ketoacidosis, History of Coronary Artery Bypass Surgery (CABG), type 1 diabetes mellitus, sever liver failure, history of any cancer and chemotherapy, history of severe allergic reaction to Empagliflozin or its formulation components, Severe renal failure (eGFR < 30 mL/minute/1.73 m²), end-stage renal disease (ESRD), or dialysis, hypovolemia, any inflammatory under treatment disease, history heart failure (HF).^{35,36} After screening medical records 55 patients met inclusion criteria. Among these, 45 patients were randomized (1:1) to receive either Empagliflozin 10 mg or matching placebo; during treatment period, 10 patients (five from each group) were excluded during follow-up (Figure 1).

Intervention, randomization and follow-up

Insulin therapy was started for all patients to manage blood glucose, and metformin was added if appropriate. To maintain optimal blood sugar level, patients' dietary recommendation during patient's nutritional counseling, the patient's blood sugar medicines are adjusted, and if necessary, insulin added to treatment, and patient's fasting blood sugar maintained at 80 – 130 mg/dL and 2 hours after meal sugar maintained at 140 – 180 mg/dL. Patients received metformin, sulfonylurea, and other anti-diabetic agents or combination of all of these were included. Those treated with older-generation of sulfonylurea, they were transitioned to newer-generation of sulfonylurea for better glycemic control. Patients were randomly assigned to receive either EMPA (10 mg tablets from Dr. Abidi Pharmaceuticals, Tehran, Iran) daily for 12 weeks, or matching placebo. EMPA was started after 24 hours of hospitalization and reperfusion, if hemodynamics were stable and the exclusion criteria were ruled out. Randomization was conducted by a third-party collaborator using coded assignment. A set of odd and even codes was drawn without replacement, ensuring unbiased assignment of drug and placebo. Peripheral blood sample was collected before of initiating of the EMPA, and again at the end of 12-week intervention.

Patients returned one month and then 3 months after PPCI to assess compliance with medication use, review drug side effects, and also control cardiovascular risk factors and EF assessment.

Gene expression analyzes

Five ml of patients' blood sample was centrifuged and buffy coat was separated and stored in -80°C until use. Total RNA was extracted by Sambio™ RNA extraction kit (Sambio™, China). The quantity of extracted RNA was analyzed by Eppendorf BioPhotometer Plus (Eppendorph, Germany). Based on concentration, RNA was adjusted for 1 μg and cDNA was synthesized by Samzol kit (sam020c, China). Gradient PCR was used to optimize annealing temperatures of primers for target and housekeeping (GAPDH) genes (60°C for CTF-1 and 59°C for both GDF-15 and GAPDH). Expression levels of target and housekeeping gene were quantified by Real-time PCR by ABI 7300 Real-Time PCR System (Applied Biosystems) with specific primers (Table 1), and analyzed by using $2^{-\Delta\Delta\text{CT}}$ method. The qRT-PCR reactions were performed using Sambio™ SYBR qPCR Master Mix (Sambio™, China) according to the manufacturer's protocol. The reaction mixture consisted of 500 ng of cDNA template, 10 μL of $2\times$ Sambio™ SYBR qPCR Master Mix, 0.4 μL of forward primer (10 μM), and 0.4 μL of reverse primer (10 μM) in a final reaction volume of 20 μL . A non-template negative control were included for each primer set to confirm the absence of genomic DNA and contamination in the reactions. The qRT-PCR protocol included an initial step of 95°C for 4 min, followed by 40 cycles of 95°C for 20 s and then annealed at 59°C (GDF-15, GAPDH) and 60°C for CTF-1) for 20 s, extension at 72°C for 40 s.

Statistical analyses

All Data are expressed as mean values, and statistical analyses were performed by SPSS version 26 (IBM, USA). Normality was assessed by the Shapiro-Wilks test. For normally distributed data, independent t test (between groups) and paired t test (within group) were used. For non-normal distributions, Mann-Whitney U test (between groups) and Wilcoxon signed-rank test (within groups) were used. Differences were considered statistically significant at P -value less than 0.05.

Results

The mean age of participants was 61.27 ± 9.07 , and 22 (66%) of patients were male. Comparing an intervention group to a placebo group, mean duration of diabetes was longer in intervention group (7.82 ± 5.13) than in the placebo group (3.75 ± 2.74). Hypertension was present

in 19 (57%) patients, ischemic heart disease present in 7 (21%), and dyslipidemia in 17 (51%) patients. The mean ejection fraction was 37.88 ± 8.104 . PCI was performed in 6 (18%), and 15 (45%) were smokers. The most common culprit vessels were the right coronary artery (RCA) in 15 (45%) patients, and left anterior descending artery (LAD) in 14 (42%) patients. RCA occlusion typically results in an inferior MI, while LAD occlusion typically led to extensive anterior infarction with greater prognostic impact (Table 2).

There were no significant differences in clinical and laboratory characteristics between two groups. Both groups showed reduction in body mass index (BMI), fasting blood glucose (FBS), low density lipoprotein (LDL), cholesterol, triglyceride and high-density lipoprotein (HDL) levels, but LDL ($P=0.045$) and triglyceride ($P=0.006$) decreased more in the intervention group (Table 3 and 4).

CTF-1 expression level was significantly lower (1-fold) in the intervention group 0.3 ± 0.28 compared to placebo group 5.66 ± 6.52 ($P=0.003$). GDF-15 expression was also reduced (7-fold) in the intervention group 0.198 ± 0.22 compared to placebo group 1.66 ± 1.04 ($P < 0.0001$). This reduction was not associated with other clinical variables (Figure 2).




Figure 1. Flowchart of project study

Table 1. Primer sequence (5' to 3') used for target amplification

Gene name	Forward primer	Reverse primer	PCR product length (bp)
CTF-1	CACTTGGAGGCCAAGATCC	TCTCCCTGGAGCTGCACAT	70
GDF-15	GTTAGCCAAAGACTGCCACTG	CCTTGAGCCCATTCCACA	106
GAPDH	CTGACCACCAACTGCTTAG	GTCTTCTGGGTGGCAGTGAT	108

Table 2. Baseline characteristics, laboratory, echocardiographic, and angiographic data

Variable	Placebo group N (%), mean (std)	Intervention group N (%), mean (std)	P value
Gender (male)	13 (81.3%)	9 (52.9%)	0.141
Diabetes duration	3.75 (2.74)	7.82 (5.13)	0.022*
History of hypertension	8 (50%)	11 (64.7%)	0.407
History of ischemic heart disease	2 (12.5%)	5 (29.4%)	0.398
History of hyperlipidemia	5 (31.3%)	12 (70.6%)	0.038*
Smoking	10 (62.5%)	5 (29.4%)	0.084
History of PCI	2 (12.5%)	4 (23.5%)	0.656
LDL (mg/dL)	98.06 (±26.144)	91.76 (±20.398)	0.612
HDL (mg/dL)	39.63 (±6.5)	37.35 (±7.407)	0.187
FBS (mg/dL)	174.94 (±61.518)	218.76 (±85.896)	0.144
Triglyceride (mg/dL)	147.5 (±52.004)	133.24 (±48.763)	0.551
Cholesterol (mg/dL)	170.81 (±52.439)	155.94 (±31.558)	0.46
BM (kg/m²)	27.03 (±2.40)	26.776 (±2.3104)	0.979
Systolic blood pressure (mmHg)	128.44 (±26.377)	122.35 (±18.844)	0.596
Diastolic blood pressure (mmHg)	79.69 (±14.659)	77.65 (±11.608)	0.793
GFR (ml/min/1.73m²)	73.63 (±10.106)	65.29 (±23.9.19)	0.256
Heart failure severity (Based on EF)			
Mild	6 (37.5%)	5 (29.4%)	0.656
Moderate	7 (43.8%)	8 (47.7%)	
Severe	3 (18.8%)	4 (23.5%)	
TIMI-before-PCI			
0	9 (56.3%)	10 (58.8%)	1
1	7 (43.8%)	7 (41.2%)	
2	0 (0%)	0 (0%)	
3	0 (0%)	0 (0%)	
TIMI-after-PCI			
0	0 (0%)	0 (0%)	0.688
1	0 (0%)	0 (0%)	
2	4 (25%)	3 (17.6%)	
3	12 (75%)	14 (82.4%)	
Culprit vessel			
LAD	6 (37.5%)	8 (47.1%)	0.382
LCX	1 (6.3%)	3 (17.7%)	
RCA	9 (56.3%)	6 (35.3%)	

Discussion

EMPA is a drug from the SGLT2 inhibitor class of drugs that is recognized as a novel drug for the treatment of T2DM. EMPA has been shown to significantly improve patients' BMI, microalbuminuria, BUN, FBS, 2-hour postprandial blood glucose, HbA1c, triglycerides, cholesterol, and LDL ($P<0.05$), while HDL levels improved without reaching statistical significance.¹ In our study, LDL and triglyceride levels improved significantly ($P<0.05$), while FBS levels improved, which was not statistically significant ($P=0.059$). These findings confirm the potential clinical benefits of EMPA.

EMPA is also known to have protective effects on

CVD, including reducing major adverse cardiovascular events (MACE) in ischemic heart disease (IHD) patients, reducing mortality and hospitalization in heart failure (HF) patients, etc. These effects include decreased blood glucose levels, decreased oxidative stress, and positive effects on cytokines and chemokines.² It also reduced the secretion of CTF-1 and GDF-15 proteins in human smooth muscle cells. CTF-1 and GDF-15 proteins are considered inflammatory factors.^{3,4} CTF-1 is highly expressed in cardiac muscle cells, cardiovascular cells, vascular epithelial cells, vascular smooth muscle cells, and macrophages.⁵⁻⁷ Chronic overexpression of this protein increases fatty acid oxidation, fibroblast growth, foam cell formation in the vascular intima, and atherosclerosis, while also increasing oxidative stress factors, cytokines, and chemokines (8). In the APOE^(-/-) mice model, it has been shown that CTF-1 protein affects the formation of atherosclerotic plaques by increasing macrophage migration, increasing expression of inflammatory factors, and increasing foam cell formation in the vascular intima.^{9,10} CTF-1 is normally expressed at low levels in monocytes, and this biomarker is highly upregulated in macrophages of atherosclerotic plaques. Studies in APOE^(-/-) mice have shown a strong correlation between CTF-1 expression and the severity of atherosclerosis.¹⁰ GDF-15 is a stress-responsive biomarker that has been associated with various cardiovascular diseases, including atherosclerotic plaque formation, IHD, heart failure, various arrhythmias, hypertension, etc.¹¹ GDF-15 is expressed at high levels in myocardial cells under inflammatory conditions, and plasma levels of GDF-15 are increased accordingly. In patients with HF with reduced ejection fraction (HFrEF), GDF-15 is increased, which is accompanied by increases in high-sensitivity C-reactive protein and high-sensitivity troponin T.¹⁹

Our study is the first to evaluate the effect of EMPA on peripheral blood CTF-1 and GDF-15 expression. In this study, we studied 33 type 2 DM patients with MI who underwent primary PCI. We found that treatment with EMPA 10 mg daily for 12 weeks resulted in a decrease in CTF-1 and GDF-15 expression in peripheral blood and peripheral circulating monocytes, suggesting a potential anti-atherosclerotic mechanism. Our data support that EMPA exerts its anti-atherosclerotic effects in part by reducing monocyte CTF-1 expression and potentially through mechanisms involving vascular smooth muscle cells. Interestingly, our data show that EMPA reduces the expression of GDF-15 in peripheral circulating monocytes, which is associated with the formation of atherosclerotic plaques. Consequently, EMPA may reduce the risk of cardiovascular disease by reducing the expression of GDF-15, which is associated with various types of cardiovascular disease.

Conclusion


In this study, we showed that EMPA reduced CTF-1 and GDF-15 expression in type 2 diabetic patients with MI who underwent primary PCI. Given the established

Table 3. Change in clinical variables and laboratory measurements after intervention between placebo and intervention group

Variable	Before intervention		P-value	After intervention		P-value
	placebo	intervention		placebo	intervention	
LDL (mg/dL)	98.06 (±26.144)	91.76 (±20.398)	0.612	66.13 (±10.601)	58.88 (±9.347)	0.045*
HDL (mg/dL)	39.63 (±6.5)	37.35 (±7.407)	0.187	50.44 (±10.347)	56.53 (±11.375)	0.138
FBS (mg/dL)	174.94 (±61.518)	218.76 (±85.896)	0.144	142.56 (±36.425)	118.29 (±22.588)	0.059
Triglyceride (mg/dL)	147.5 (±52.004)	133.24 (±48.763)	0.551	100.38 (±23.174)	74.29 (±26.224)	0.006**
Cholesterol (mg/dL)	170.81 (±52.439)	155.94 (±31.558)	0.46	125.69 (±21.291)	130.41 (±22.344)	0.539
BMI kg/m ²	27.03 (±2.4025)	26.776 (±2.3104)	0.979	26.681 (±2.3022)	26.335 (±2.3208)	0.908
Systolic blood pressure (mmHg)	128.44 (±26.377)	122.35 (±18.844)	0.596	121.88 (±8.539)	122.06 (±8.849)	0.923
Diastolic blood pressure (mmHg)	79.69 (±14.659)	77.65 (±11.608)	0.793	77.19 (±7.739)	74.41 (±8.269)	0.375
GFR (ml/min/1.73m ²)	73.63 (±10.106)	65.29 (±23.919)	0.256	75.56 (±20.043)	66.18 (±18.375)	0.159

Table 4. Change in clinical variables and laboratory measurements after intervention in each group before and after intervention

Variable	Before intervention		P-value	After intervention		P-value
	placebo	intervention		placebo	intervention	
LDL (mg/dL)	98.06 (±23.144)	66.13 ((±10.601)	<0.001***	91.76 ((±20.398)	58.88 ((±9.347)	<0.001***
HDL (mg/dL)	39.63 (±6.5)	50.44 ((±10.347)	<0.001***	37.35 ((±7.407)	56.53 ((±11.357)	<0.001***
FBS (mg/dL)	174.94 (±61.518)	142.56 ((±36.245)	<0.001***	218.76 ((±85.896)	118.29 ((±22.588)	<0.001***
Triglyceride (mg/dL)	147.5 (±52.004)	100.38 ((±23.174)	<0.001***	133.24 ((±48.763)	74.29 ((±26.224)	<0.001***
Cholesterol (mg/dL)	170.81 ((±52.439)	125.69 ((±21.291)	<0.001***	155.94 ((±31.558)	130.41 ((±22.344)	<0.001***
BMI kg/m ²	27.03 (±2.40)	26.681 ((±2.30)	0.002**	26.776 ((±2.31)	26.335 ((±2.32)	0.003**
Systolic blood pressure (mmHg)	128.44 (±26.37)	121.88 ((±8.53)	0.422	122.35 ((±18.84)	122.06 ((±8.84)	0.886
Diastolic blood pressure (mmHg)	79.69 (±14.65)	77.19 ((±7.73)	0.371	77.65 ((±11.60)	74.41 (±8.26)	0.25
GFR (ml/min/1.73m ²)	73.63 (±10.109)	75.56 ((±20.043)	0.096	65.29 ((±23.919)	66.18 ((±18.375)	0.969

**Figure 2.** CTF-1 and GDF-15 gene expression, control level considered 1

roles of CTF-1 and GDF-15 as cardiovascular biomarker, their decreased expression suggests potential cardio-protective benefits of EMPA. Further large-scale studies are recommended to confirm the potential benefits of EMPA in managing atherosclerosis in patients after MI.

Authors' Contribution

Conceptualization: Ali Ramazani, Reza Madadi.

Data Curation: Reza Rastgoo, Mahnaz Yousefi Ramandi, Fereshteh Ebrahimi.

Investigation: Reza Rastgoo, Mahnaz Yousefi Ramandi, Fereshteh Ebrahimi,

Methodology Reza Rastgoo, Mahnaz Yousefi Ramandi, Fereshteh Ebrahimi

Supervision: Ali Ramazani, Reza Madadi.

Writing–Original Draft: Reza Rastgoo

Writing–Review & Editing: Ali Ramazani, Hamid Khederlo.

Competing Interests

There is no conflict of interest.

Ethical Approval

This study was approved by the Ethics Committee of Zanjan University of Medical Sciences (approval code: Ethical code: IR.ZUMS.REC.1403.154) and the protocol was prospectively registered on the Iranian Registry of Clinical Trials (www.IRCT.ir, IRCT code: IRCT20241106063619N1). Furthermore, all participants received and signed written informed consent.

Funding

None.

References

- Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. *Eur Heart J* 2013;34(39):3028-34. doi:10.1093/eurheartj/eh356
- Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med* 2013;368(21):2004-13. doi:10.1056/NEJMra1216063
- Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 2000;20(5):1262-75. doi:10.1161/01.atv.20.5.1262
- Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. *Nature* 2012;487(7407):325-9. doi:10.1038/nature11260
- Zaheen M, Pender P, Dang QM, Sinha E, Chong JJ, Chow CK, et al. Myocardial infarction in the young: aetiology, emerging risk factors, and the role of novel biomarkers. *J Cardiovasc Dev Dis* 2025;12(4):148. doi:10.3390/jcdd12040148
- Pletsch-Borba L, Grafetstätter M, Hüsing A, González Maldonado S, Kloss M, Groß ML, et al. Biomarkers of vascular injury in relation to myocardial infarction risk: a population-based study. *Sci Rep* 2019;9(1):3004. doi:10.1038/s41598-018-38259-y
- Caliskan S, Besli F, Yildirim A, Gungoren F, Alisir MF, Polat U, et al. The relationship between cardiotrophin-1 and troponin-I in coronary arterial bypass grafting on the beating heart: a prospective study. *Heart Surg Forum* 2015;18(4): E146-50. doi:10.1532/hfs.1386
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018;14(2):88-98. doi:10.1038/nrendo.2017.151
- Malek R, Hannat S, Nechadi A, Mekideche FZ, Kaabeche M. Diabetes and Ramadan: a multicenter study in Algerian population. *Diabetes Res Clin Pract* 2019;150:322-30. doi:10.1016/j.diabres.2019.02.008
- Patoulas D, Papadopoulos C, Stavropoulos K, Zografou I, Doumas M, Karagiannis A. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: the potential role of sodium-glucose co-transporter-2 inhibitors. *J Clin Hypertens (Greenwich)* 2020;22(4):562-71. doi:10.1111/jch.13831
- Liakopoulos V, Franzén S, Svensson AM, Miftaraj M, Ottosson J, Näslund I, et al. Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study. *BMJ Open* 2019;9(1): e023882. doi:10.1136/bmjopen-2018-023882
- Armiliotta M, Angeli F, Paolisso P, Belmonte M, Raschi E, Di Dalmazi G, et al. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure. *Pharmacol Ther* 2025;270:108861. doi:10.1016/j.pharmthera.2025.108861
- Larkin HD. FDA expands empagliflozin heart failure indication. *JAMA* 2022;327(13):1219. doi:10.1001/jama.2022.3970
- Frampton JE. Empagliflozin: a review in type 2 diabetes. *Drugs* 2018;78(10):1037-48. doi:10.1007/s40265-018-0937-z
- Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. *Cardiovasc Diabetol* 2025;24(1):227. doi:10.1186/s12933-025-02777-7
- Behzad H, Mashayekhi S, Asham H, Sarbakhsh P, Entezari-Maleki T. Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: a double-blind, randomized clinical trial. *J Cardiovasc Thorac Res* 2024;16(2):113-9. doi:10.34172/jcvtr.33103
- Califf RM. Biomarker definitions and their applications. *Exp Biol Med (Maywood)* 2018;243(3):213-21. doi:10.1177/1535370217750088
- Berezin AE, Berezin AA. Circulating cardiac biomarkers in diabetes mellitus: a new dawn for risk stratification-a narrative review. *Diabetes Ther* 2020;11(6):1271-91. doi:10.1007/s13300-020-00835-9
- Chandrasekar B, Mummidi S, DeMarco VG, Higashi Y. Empagliflozin reverses oxidized LDL-induced RECK suppression, cardiotrophin-1 expression, MMP activation, and human aortic smooth muscle cell proliferation and migration. *Mediators Inflamm* 2023;2023:6112301. doi:10.1155/2023/6112301
- Omar M, Jensen J, Kistorp C, Højlund K, Videbæk L, Tuxen C, et al. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). *Cardiovasc Diabetol* 2022;21(1):34. doi:10.1186/s12933-022-01463-2
- Ferreira JP, Packer M, Butler J, Filippatos G, Pocock SJ, Januzzi JL, et al. Growth differentiation factor-15 and the effect of empagliflozin in heart failure: findings from the EMPEROR program. *Eur J Heart Fail* 2024;26(1):155-64. doi:10.1002/ejhf.3078
- Hogas S, Bilha SC, Branisteanu D, Hogas M, Gaipov A, Kanbay M, et al. Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. *Arch Med Sci* 2017;13(4):897-913. doi:10.5114/aoms.2016.58664
- Tokmachev RE, Kravchenko AY, Budnevsky AV, Chernik TA, Tokmachev EV, Shkatova YS. Potential biomarkers for heart failure diagnostics and management. *Pak J Med Health Sci* 2021;14(4):1813-6.
- Konii H, Sato K, Kikuchi S, Okiyama H, Watanabe R, Hasegawa A, et al. Stimulatory effects of cardiotrophin 1 on atherosclerosis. *Hypertension* 2013;62(5):942-50. doi:10.1161/hypertensionaha.113.01653
- López-Yoldi M, Marcos-Gomez B, Romero-Lozano MA, Sáinz N, Prieto J, Martínez JA, et al. Cardiotrophin-1 regulates adipokine production in 3T3-L1 adipocytes and adipose tissue from obese mice. *J Cell Physiol* 2017;232(9):2469-77. doi:10.1002/jcp.25590
- Vlahodimitris I, Karangelis D, Moschaki M, Moyssakis I, Christodoulou KC, Perrea DN, et al. Cardiotrophin-1 in asymptomatic hypertensive patients with mild diastolic dysfunction: potential prognostic value in early stages of hypertensive heart disease. *Cureus* 2023;15(10): e46516. doi:10.7759/cureus.46516
- Dunaieva IP. Cardiotrophin-1 as a prognostic biomarker of hypertension and a key regulator of cardiac glucose metabolism. *Int J Endocrinol* 2023;19(2):106-10. doi:10.22141/2224-0721.19.2.2023.1254
- Fritzenwanger M, Jung C, Franz M, Foerster M, Figulla HR. Immunomodulatory effects of cardiotrophin-1 on in vitro cytokine production of monocytes & CD4 + T-lymphocytes. *Indian J Med Res* 2012;136(3):471-6.

29. Fritzenwanger M, Meusel K, Foerster M, Kueth F, Krack A, Figulla HR. Cardiotrophin-1 induces interleukin-6 synthesis in human monocytes. *Cytokine* 2007;38(3):137-44. doi:[10.1016/j.cyto.2007.05.015](https://doi.org/10.1016/j.cyto.2007.05.015)
30. Ichiki T, Jougasaki M, Setoguchi M, Imamura J, Nakashima H, Matsuoka T, et al. Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. *Am J Physiol Heart Circ Physiol* 2008;294(2): H750-63. doi:[10.1152/ajpheart.00161.2007](https://doi.org/10.1152/ajpheart.00161.2007)
31. Luo JW, Duan WH, Song L, Yu YQ, Shi DZ. A meta-analysis of growth differentiation factor-15 and prognosis in chronic heart failure. *Front Cardiovasc Med* 2021;8:630818. doi:[10.3389/fcvm.2021.630818](https://doi.org/10.3389/fcvm.2021.630818)
32. Wang J, Wei L, Yang X, Zhong J. Roles of growth differentiation factor 15 in atherosclerosis and coronary artery disease. *J Am Heart Assoc* 2019;8(17): e012826. doi:[10.1161/jaha.119.012826](https://doi.org/10.1161/jaha.119.012826)
33. Chen M, Ding N, Mok Y, Mathews L, Hoogeveen RC, Ballantyne CM, et al. Growth differentiation factor 15 and the subsequent risk of atrial fibrillation: the atherosclerosis risk in communities study. *Clin Chem* 2022;68(8):1084-93. doi:[10.1093/clinchem/hvac096](https://doi.org/10.1093/clinchem/hvac096)
34. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K, et al. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. *Cell Tissue Res* 2004;318(2):325-33. doi:[10.1007/s00441-004-0986-3](https://doi.org/10.1007/s00441-004-0986-3)
35. Choobkar S, Alilou M, Mahmoudvand G, Karimi Rouzbahani A. Evaluation of the effects of empagliflozin on serum levels of triglycerides and cholesterol in patients with type 2 diabetes mellitus and hypertriglyceridemia: a prospective study. *Iran J Diabetes Obes* 2024;16(4):213-20. doi:[10.18502/ijdo.v16i4.17287](https://doi.org/10.18502/ijdo.v16i4.17287)
36. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373(22):2117-28. doi:[10.1056/NEJMoa1504720](https://doi.org/10.1056/NEJMoa1504720)